1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Real-time Estimate Cboe BZX  -  05/27 11:40:12 am EDT
5.125 USD   +1.08%
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
4.64(c) 4.62(c) 4.63(c) 5.07(c) 5.04 Last
23 569 20 172 14 250 26 390 6 409 Volume
-2.93% -0.43% +0.22% +9.50% -0.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 53,4 M - -
Net income 2022 -35,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,44x
Yield 2022 -
Sales 2023 66,0 M - -
Net income 2023 -30,3 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,87x
Yield 2023 -
Capitalization 82,4 M 82,4 M -
Capi. / Sales 2022 1,54x
Capi. / Sales 2023 1,25x
Nbr of Employees 221
Free-Float 58,9%
More Financials
Company
Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE... 
More about the company
Ratings of Exagen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about EXAGEN INC.
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/11Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11TRANSCRIPT : Exagen Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M
MT
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
GL
05/11Exagen Inc. Reports First Quarter 2022 Results
GL
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
AQ
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
CI
05/11Exagen Inc. Reports First Quarter 2022 Results
AQ
More news
News in other languages on EXAGEN INC.
05/16Exagen Inc. étend sa couverture avec Alivio Health, s'associant pour fournir des tests ..
05/11Exagen Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2022
05/11Earnings Flash (XGN) EXAGEN annonce un chiffre d'affaires de 10,4 millions de dollars p..
05/11Exagen Inc. Annonce d'un nouveau code PLA et du prix Medicare pour le test propriétaire..
05/11Exagen Inc. Révise ses prévisions de revenus pour l'ensemble de l'année 2022
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,07 $
Average target price 16,40 $
Spread / Average Target 223%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer